The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.

Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.

Insteel (IIIN)

Consensus Price Target: $37 (21.9% implied return)

Growing from a small wire manufacturer to one of the largest in the U.S., Insteel (NYSE: IIIN) provides steel wire reinforcing products for concrete.

Why Is IIIN Not Exciting?

1. Muted 5.9% annual revenue growth over the last five years shows its demand lagged behind its industrials peers
2. Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 5 percentage points
3. Shrinking returns on capital suggest that increasing competition is eating into the company’s profitability

Insteel’s stock price of $30.37 implies a valuation ratio of 17.4x forward P/E. Dive into our free research report to see why there are better opportunities than IIIN.

Neogen (NEOG)

Consensus Price Target: $12 (28.8% implied return)

Founded in 1981 and operating at the intersection of food safety and animal health, Neogen (NASDAQ: NEOG) develops and manufactures diagnostic tests and related products to detect dangerous substances in food and pharmaceuticals for animal health.

Why Do We Think NEOG Will Underperform?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.2% annually over the last two years
2. Diminishing returns on capital from an already low starting point show that neither management’s prior nor current bets are going as planned
3. Unprofitable operations could lead to additional rounds of dilutive equity financing if the credit window closes

Neogen is trading at $9.32 per share, or 33.3x forward P/E. To fully understand why you should be careful with NEOG, check out our full research report (it’s free).

Fiserv (FISV)

Consensus Price Target: $70 (38.4% implied return)

Powering over 1 billion accounts and processing more than 12,000 financial transactions per second globally, Fiserv (NASDAQ: FISV) provides payment processing and financial technology solutions that enable merchants, banks, and credit unions to accept payments and manage financial transactions.

Why Should You Dump FISV?

1. Annual sales growth of 4.1% over the last two years lagged behind its financials peers as its large revenue base made it difficult to generate incremental demand
2. Annual earnings per share growth of 2.8% underperformed its revenue over the last two years, showing its incremental sales were less profitable
3. Low return on equity reflects management’s struggle to allocate funds effectively

At $50.57 per share, Fiserv trades at 6x forward P/E. If you’re considering FISV for your portfolio, see our FREE research report to learn more.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.